Last edition
News about "Progression-Free Survival"
Pfizer Launches Elranatamab in India for Relapsed or Refractory Multiple Myeloma
Pfizer has launched Elranatamab in India for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have received at least four prior therapies. The BCMA-directed bispecific antibody is available as a fixed-dose subcutaneous injection, offering a novel treatment option for heavily pretreated multiple myeloma patients.
Progression-free Survival | 03/06/2026 | By News Bureau
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Progression-Free Survival | 30/05/2026 | By News Bureau
Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC
Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.
Progression-Free Survival | 30/05/2026 | By News Bureau
Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer
Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
Progression-free Survival | 19/05/2026 | By News Bureau | 110
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Progression-Free Survival | 07/05/2026 | By News Bureau | 106
Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer
Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).
Progression-Free Survival | 21/03/2026 | By News Bureau
Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC
Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.
Progression-Free Survival | 13/02/2026 | By News Bureau | 184
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
Progression-Free Survival | 19/01/2026 | By News Bureau | 197
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy